AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer. The approval is for the use of ...

The Association of the British Pharmaceutical Industry (ABPI) has said that the new 10-year plan for the NHS has underplayed ...

London’s FTSE 100 was flat at 8,824.61 in quiet afternoon trade on Friday, with US markets closed for Independence Day.

London stocks ended Thursday little changed at the top tier but weaker further down the board, as investors weighed fresh ...

The pound was quoted down at USD1.3650 at midday on Friday in London, compared to USD1.3654 at the equities close on Thursday. The euro stood higher at USD1.778, against USD1.1762. Against the yen, ...